KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cme (CME) EBITDA Margin (2016 - 2025)

Cme (CME) has disclosed EBITDA Margin for 17 consecutive years, with 61.84% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 25.0% to 61.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 66.11%, a 55.0% increase, with the full-year FY2025 number at 64.86%, up 73.0% from a year prior.
  • EBITDA Margin was 61.84% for Q4 2025 at Cme, down from 64.97% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 69.13% in Q1 2025 to a low of 55.06% in Q4 2021.
  • A 5-year average of 63.13% and a median of 63.45% in 2022 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 818bps in 2021; the steepest drop was -453bps in 2021.
  • Cme's EBITDA Margin stood at 55.06% in 2021, then grew by 0bps to 55.33% in 2022, then increased by 8bps to 59.97% in 2023, then rose by 4bps to 62.09% in 2024, then decreased by 0bps to 61.84% in 2025.
  • Per Business Quant, the three most recent readings for CME's EBITDA Margin are 61.84% (Q4 2025), 64.97% (Q3 2025), and 68.36% (Q2 2025).